| Next 10 |
TYRA News and Press, Tyra Tech Inc
-
H.C. Wainwright analyst Mitchell Kapoor initiated coverage of Tyra Biosciences (TYRA) with a Buy rating and $12 price target. The biotech company focused on development of therapies to combat acquired drug resistance across various cancers has a proprietary in-house discovery platform an...
-
Tyra Biosciences press release (NASDAQ:TYRA): Q1 GAAP EPS of -$0.36 misses by $0.16. As of March 31, 2022, TYRA had cash and cash equivalents of $292.5 million. For further details see: Tyra Biosciences GAAP EPS of -$0.36 misses by $0.16
-
Tyra Biosciences Reports First Quarter 2022 Financial Results and Highlights PR Newswire -Pipeline on-track; INDs to be filed for TYRA-300 and TYRA-200 in 2022- -Well-capitalized with cash and cash equivalents of $292.5 million as of Q1 2022- CARL...
-
The following slide deck was published by Tyra Biosciences, Inc. in conjunction with this event. For further details see: Tyra Biosciences (TYRA) Investor Presentation - Slideshow
-
Tyra Biosciences press release (NASDAQ:TYRA): Q4 GAAP EPS of -$0.24. Q4 Net loss $9.9M For further details see: Tyra Biosciences GAAP EPS of -$0.24
-
Tyra Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights -Pipeline on-track; INDs expected to be filed for TYRA-300 and TYRA-200 in 2022- -Strengthened organization with key appointment to clinical team- -Well-capitalized with cash and ...
-
Tyra Biosciences to Participate in Cowen 42nd Annual Healthcare Conference PR Newswire CARLSBAD, Calif. , Feb. 22, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome t...
-
Tyra Biosciences (TYRA +14.0%) owner Boxer Capital bought 125,000 shares at $13.12 per share. The transaction was worth $1.6M. This brings his total share holding to ~6.44M shares Form 4 The stock has a market cap of $497.1M. For further details see: Tyra Biosciences surges 14% as owner...
-
Gainers: Galera Therapeutics (NASDAQ:GRTX) +11%. TFF Pharmaceuticals TFFP +7%. Annexon (NASDAQ:ANNX) +6%. Clarus Therapeutics Holdings (NASDAQ:CRXT) +4%. Tyra Biosciences (NASDAQ:TYRA) +4%. Losers: CalAmp CAMP -14%. Qilian International Holding Group (NASDAQ:QLI) -4%...
-
The value of IPOs in the first half of this year surpassed mid-pandemic levels. However, since the Fed intends to start tightening its monetary policy later this month and inflation is rising, many recently listed stocks could suffer. Hence, we think it might be best to avoid the recent IPO s...
Stock Information
MENU
TYRA
TYRA Quote
TYRA Short
TYRA News
TYRA Articles
Get TYRA Alerts
News, Short Squeeze, Breakout and More Instantly...
-
Tyra Biosciences Reports First Quarter 2022 Financial Results and Highlights PR Newswire -Pipeline on-track; INDs to be filed for TYRA-300 and TYRA-200 in 2022- -Well-capitalized with cash and cash equivalents of $292.5 million as of Q1 2022- CARL...
-
Tyra Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights -Pipeline on-track; INDs expected to be filed for TYRA-300 and TYRA-200 in 2022- -Strengthened organization with key appointment to clinical team- -Well-capitalized with cash and ...
-
Tyra Biosciences to Participate in Cowen 42nd Annual Healthcare Conference PR Newswire CARLSBAD, Calif. , Feb. 22, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome t...